Yes — SSRIs, Wellbutrin®, and other antidepressants are commonly prescribed alongside semaglutide or tirzepatide, and no established direct interaction between GLP-1 medications and antidepressants as a class prevents combining them. What actually matters is more specific than "will they interact": which antidepressant you're on affects appetite and weight differently, and both of your prescribers need the full picture before you start. Never stop or change either medication on your own to manage a perceived interaction.
The one-paragraph version
No direct interaction between GLP-1 medications and antidepressants as a class has been established. What differs is the antidepressant itself: some SSRIs are associated with weight gain in some patients, while bupropion (Wellbutrin®) works through a different mechanism and is generally associated with modest weight loss rather than gain — a difference worth discussing with your prescriber if weight is part of your treatment goal. Tell both prescribers about both medications, and let each clinician manage their own prescription rather than guessing at how the other one interacts.
Why this combination comes up so often
Depression and anxiety are common, and so is obesity — the two conditions overlap in the population more than chance would predict, and each can make the other harder to manage. It's routine for someone starting GLP-1 therapy to already be on an SSRI, an SNRI, bupropion, or another antidepressant, prescribed by a psychiatrist or primary care doctor who isn't the same clinician managing their weight care.
That split is exactly where coordination gaps happen. A GLP-1 prescriber who doesn't know you're on an antidepressant can't factor in appetite or GI-symptom overlap; an antidepressant prescriber who doesn't know you've started a GLP-1 can't help you sort out which medication is behind a new symptom. Neither gap is dangerous by itself, but both are avoidable with a complete medication list.
SSRIs and GLP-1s: where the overlap actually is
Selective serotonin reuptake inhibitors — sertraline, escitalopram, fluoxetine, and others — don't share a metabolic pathway with semaglutide or tirzepatide, and there's no established pharmacologic interaction between them. The overlap that matters is practical, not chemical:
- GI side effects can stack early on. Nausea is a common side effect when starting or increasing an SSRI, and it's also the most common GLP-1 side effect, especially after each dose increase. If both effects show up around the same time, it can be hard to tell which medication is responsible — worth mentioning to whichever prescriber you reach first.
- Weight effects vary by SSRI and by person. Some SSRIs are associated with weight gain over time in some patients, particularly with longer use; others are closer to weight-neutral. This varies enough by individual that it isn't useful to generalize across the whole class — it's a conversation for your prescriber, not something to assume from the medication name alone.
- Appetite changes can blur together. GLP-1 medications reduce appetite by design. Some antidepressants also affect appetite, in either direction. If your eating patterns shift after starting both around the same time, your care team benefits from knowing the full timeline.
None of this is a reason to avoid combining the two — it's a reason to give both prescribers complete information so they can offer personalized guidance on managing side effects and expectations.
Wellbutrin (bupropion) and weight
Bupropion works differently from SSRIs — it's a norepinephrine-dopamine reuptake inhibitor rather than a serotonergic medication, and it's the one commonly prescribed antidepressant that's generally associated with modest weight loss rather than weight gain. That's a meaningfully different starting point if weight is part of what you and your clinicians are managing.
This doesn't mean bupropion and a GLP-1 are a specifically better or more effective pairing than any other combination — no such comparison has been established, and this article isn't suggesting one. It means the weight-related conversation with your prescriber will likely go differently than it would with a medication associated with weight gain. Your psychiatric prescriber and your GLP-1 prescriber are each responsible for their own medication; neither one should adjust the other's prescription without talking to you and, ideally, to each other.
Never stop or adjust either medication on your own
If you're worried about an interaction, message your prescriber — don't stop your antidepressant, skip a GLP-1 dose, or change either medication's dosage or timing without medical guidance. Abruptly stopping certain antidepressants can cause withdrawal-like symptoms, and abruptly stopping a GLP-1 has its own considerations. Let the clinicians who prescribed each medication make that call.
Does a GLP-1 affect mood?
This is a fair question, given that FDA-approved labeling for weight-management GLP-1s previously included guidance on monitoring for new or worsening depression or suicidal thoughts and behaviors. That warning was included because similar concerns had been associated with older weight loss drugs, not because GLP-1s are known to cause these symptoms.
More recent FDA reviews have been reassuring. After analyzing 91 placebo-controlled trials involving nearly 108,000 people, the FDA found no increased risk of suicidality, anxiety, depression, or psychosis with GLP-1 medications. Based on those findings, the FDA asked drugmakers to remove the warning from the labeling.
That said, contact your prescriber promptly if you notice new or worsening changes in your mood, the same way you'd report any other new symptom. If you ever have thoughts of harming yourself, get help right away — call 911 or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room.
If you have a current or past mental health condition, mention it during intake regardless of whether you're currently on medication for it. It doesn't automatically rule out GLP-1 therapy — it's context your clinician uses to decide whether treatment is appropriate and what to watch for.
Timing, if you're on an oral GLP-1 tablet
GLP-1 medications slow stomach emptying, which is part of how they reduce appetite. For most oral antidepressants, taken with or without food depending on the specific drug, this doesn't require a specific timing change.
However, timing matters if you're prescribed the oral semaglutide tablet, which has specific fasting and timing instructions. Ask your prescriber how to space the two if your schedules overlap; for a weekly injection, day-to-day timing overlap with a daily oral antidepressant is minimal.
| Your antidepressant | What to flag for your GLP-1 prescriber |
|---|---|
| SSRI (sertraline, escitalopram, etc.) | Note any recent dose change — helps distinguish new GI symptoms from GLP-1 titration |
| SNRI (venlafaxine, duloxetine, etc.) | Same GI-symptom timing note as SSRIs |
| Bupropion (Wellbutrin®) | Mention if weight is part of your antidepressant treatment goal, alongside your GLP-1 goal |
| Any oral antidepressant, if you're prescribed an oral GLP-1 tablet | Ask about spacing around food/timing instructions |
How a clinician thinks through the combination
- A complete medication list, both directions. Your GLP-1 prescriber needs your antidepressant, dose, and how long you've been on it; your antidepressant prescriber needs to know you've started a GLP-1.
- A baseline before starting. Knowing your typical GI symptoms, appetite, and mood before adding a GLP-1 makes it easier to attribute any changes correctly afterward.
- Mood monitoring as standard practice, not a red flag. Reporting new or worsening mood symptoms is routine guidance for anyone on a weight-management medication — it isn't a sign something has gone wrong.
- No unilateral changes. Dose adjustments, timing changes, or stopping either medication go through the clinician who prescribed it — never self-directed based on an assumed interaction.
Where Pallas fits
Your Pallas intake asks about all of your current medications, including any antidepressants and other mental health treatment, as part of your full history — not as a disqualifying checkbox. A US-licensed clinician reviews that information before determining whether GLP-1 therapy is appropriate and which option, compounded or FDA-approved, fits your situation. If you're already working with a psychiatrist or therapist, your Pallas clinician factors that into your plan, and you're encouraged to keep both care teams informed of what the other has prescribed.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Bottom line: Antidepressants and GLP-1 therapy are frequently prescribed together, and no established direct interaction between them as a class stands in the way. What's worth a specific conversation is which antidepressant you're on — SSRIs and bupropion differ in their weight-related effects — and keeping both prescribers informed so early GI symptoms, appetite changes, or mood changes get attributed correctly. Never adjust either medication on your own; let the clinician who prescribed it make that call.
If you're also managing a thyroid medication, see how GLP-1s and levothyroxine interact. For a full rundown of what to expect physically, read our guide to GLP-1 side effects. For the basics on how these medications work, start with our GLP-1 treatment overview.
